Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 532Pituitary Neoplasms 188Multiple Endocrine Neoplasia Type 1 187Thyroid Cancer, Papillary 178Pheochromocytoma 153Carcinoma, Neuroendocrine 140Thyroid Neoplasms 130Neoplasms 107Paraganglioma 99Carcinoid Tumor 99Adrenocortical Carcinoma 92Thyroid Carcinoma, Anaplastic 82Pancreatic Neoplasms 69Neoplasm Metastasis 67Insulinoma 61Adrenal Gland Neoplasms 61Carcinoma, Medullary 59Gastro-enteropancreatic neuroendocrine tumor 58Adenocarcinoma, Follicular 58Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 56Adenoma, Islet Cell 56Lung Neoplasms 50Sarcoma 49Colorectal Neoplasms 49Carcinoma, Renal Cell 49Melanoma 47Small Cell Lung Carcinoma 45Prostatic Neoplasms 44Head and Neck Neoplasms 43

Interventions

Random Allocation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoid Tumors, Intestinal × Endocrine × Clear all
NCT07087054 2026-04-30

CAREFNDR

Crinetics Pharmaceuticals Inc.

Phase 3 Recruiting
141 enrolled
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Crinetics Pharmaceuticals Inc.

Phase 2 Completed
36 enrolled 19 charts
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡